Ipamorelin
Ipamorelin. A synthetic pentapeptide that binds the ghrelin receptor and releases growth hormone without touching cortisol, prolactin, or any other pituitary axis. The first growth hormone secretagogue with the selectivity of GHRH and the potency of a GHRP. Clean signal. No endocrine noise.
Clinician-prescribed. Ships from a licensed U.S. pharmacy.
Growth Hormone Without the Noise.
Previous growth hormone secretagogues all carried the same problem: they released GH effectively but also spiked cortisol, prolactin, and appetite through off-target receptor activity. The therapeutic benefit came with hormonal disruption that undermined it. Ipamorelin solved this. It binds GHS-R1a on pituitary somatotrophs and triggers GH release through a phospholipase C/calcium pathway without activating the HPA axis. At doses 200x above the effective GH-releasing dose, cortisol and ACTH remained at baseline. This selectivity makes Ipamorelin the first GHRP-class compound with a safety profile comparable to GHRH itself.
The Evidence
Conventional GH Approaches vs. Ipamorelin (Selective Growth Hormone Secretagogue)
| Conventional GH Approaches | Ipamorelin (Selective Growth Hormone Secretagogue) |
|---|---|
| Exogenous HGH bypasses pituitary, risks gland atrophy over time | Stimulates endogenous GH release, pituitary stays active |
| GHRP-6 and GHRP-2 raise cortisol, prolactin, and appetite | Zero cortisol, prolactin, or ACTH elevation at any dose tested |
| Hexarelin produces rapid desensitization at the receptor level | No receptor desensitization documented in clinical literature |
| MK-677 (oral) causes water retention, appetite increase, insulin resistance | No oral-related insulin or appetite disruption |
| All previous GHRPs traded GH release for hormonal side effects | GH selectivity equivalent to endogenous GHRH itself |
| Supraphysiologic elevation disrupts natural pulsatile rhythm | Pulsatile release pattern preserves natural circadian rhythm |
Details
Ipamorelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering calcium-mediated exocytosis of stored GH granules. The release pattern is pulsatile, mimicking natural circadian GH secretion rather than the flat supraphysiologic elevation of exogenous HGH.
In landmark 1998 pharmacological studies, Ipamorelin did not raise ACTH or cortisol at any dose tested, including doses 200-fold above the GH-releasing ED50. No other GHRP had ever achieved this selectivity.
Disclaimer and Transparency
Important Information About Compounded Injectables
- Compounded medications are not reviewed or approved by the FDA and do not undergo the same pre-market evaluation as FDA-approved drugs.
- IVUSE peptide injections are prepared using peptide ingredients by FDA-registered, U.S.-licensed 503A & 503B compounding pharmacies, where available and clinically appropriate.
- Availability and formulation may vary based on state regulations, evolving clinical guidance, and pharmacy partners.
All prescriptions, treatment decisions, and care plans are made independently by licensed healthcare providers using their professional judgment. Images and product depictions are for illustration only; actual packaging and supplies may vary.
*If you are interested in a prescription product, IVUSE will coordinate a telehealth visit with a licensed medical provider who will determine whether you are an appropriate candidate based on your health profile and current standards of care. If approved, a prescription will be issued and filled by one of our partner pharmacies. All prescriptions are subject to provider discretion and clinical appropriateness.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All information provided here is for educational purposes only and does not replace personalized medical advice from a qualified healthcare professional.
Stop the medication and contact your provider if you experience persistent or concerning symptoms. Seek immediate medical care if you develop signs of a severe allergic reaction (such as hives, facial swelling, or difficulty breathing) or any rapidly worsening symptom.
What happens next
Choose Your Protocol
No consultation fee. No hidden costs. Single vials or a full 12-week cycle.
Complete Your Clinical Intake
A board-certified clinician reviews your health history, medications, and goals. Asynchronous. No appointments. No waiting rooms.
Your Prescription Ships
Compounded by a licensed U.S. pharmacy. Delivered to your door in 2-4 business days. Cold-shipped when required.
Stack Your Protocol
CJC-1295
Synergistic GH elevation for deeper fat loss and lean muscle growth. CJC-1295 extends GHRH activity while Ipamorelin triggers clean GH pulses, producing longer, stronger release than either alone.
TB-500
Amplifies muscle repair and tissue regeneration. Ipamorelin drives the GH pulse that primes anabolic signaling, and TB-500 accelerates the structural repair that follows.
MOTS-C
Boosts metabolic output and ATP production. MOTS-C shifts the body toward efficient fuel use while Ipamorelin drives the GH release that mobilizes fat for it to burn.
